About
Physician and pharmacist. My experience runs from preclinical work through launch and includes business development, capital raising, investor relations, and work with Congress.
I design and build AI tools for drug development work myself.
- Malvern, Pennsylvania
- MD, Drexel University
- BS in Pharmacy, Temple University
- New York medical license 237105 (active)
Experience
- 2025 to Present
Chief Development Officer
Aquestive Therapeutics, Warren, NJHead of R&D and head of search and evaluation.
- 2024 to 2025
Chief Medical Officer
Neuvivo, Palo Alto, CAReached agreement with FDA on an approval pathway for NP001 in ALS, ending a 7-year regulatory standstill.
- 2022 to 2024
Chief Operating Officer and Chief Medical Officer
Tiziana Life Sciences, London, UK (based in Doylestown, PA)Joined as Chief Medical Officer and was promoted to Chief Operating Officer within 6 months, holding both roles. Saved $12M in the first year by reprioritizing the portfolio and restored NASDAQ compliance.
- 2017 to 2022
Global Head of Branded R&D; Chief Scientific Officer (previously Chief Medical Officer)
Endo Pharmaceuticals, Malvern, PALed an R&D organization of 1,200 people. Cut R&D cost by $55M a year and secured BLA approval for QWO 2 months ahead of the PDUFA date.
- 2014 to 2016
Chief Medical Officer
Lupin, Baltimore, MDConceived the Impleko 505(b)(2) program and led the program and team until leaving Lupin (FDA approved Impleko in 2020). Led the due diligence behind the acquisition of Solosec.
- 2005 to 2013
Chief Medical Officer and Senior Vice President
URL Pharma, Philadelphia, PAWon FDA approval of Colcrys in 3 indications. Member of the executive team that sold the company to Takeda for $3.2B.
FDA approvals
Did the clinical or FDA work on these 9 approvals.
Approved after he had moved on
Sculptra (PMA team; approved 2004), Solosec (due diligence; approved 2017), and Impleko (his concept; approved 2020).
Each tile opens the FDA record. NDA: New Drug Application. BLA: Biologics License Application. PMA: Premarket Approval.
Patents and publications
17 Orange Book patents for ColcrysInventor on all 17, sole inventor on 15. Eleven were granted within 12 months of filing.
| US 7,601,758 | Colchicine dosing and drug interactions | Oct 13, 2009 |
| US 7,619,004 | Concomitant administration with macrolides | Nov 17, 2009 |
| US 7,820,681 | Prophylaxis of gout flares | Oct 26, 2010 |
| US 7,906,519 | Concomitant administration of colchicine | Mar 15, 2011 |
| US 7,915,269 | Concomitant administration of colchicine | Mar 29, 2011 |
| US 7,935,731 | Colchicine dosing during macrolide therapy | May 3, 2011 |
| US 7,964,647 | Ultrapure colchicine compositions | Jun 21, 2011 |
| US 7,964,648 | Concomitant administration dosing methods | Jun 21, 2011 |
| US 7,981,938 | Colchicine compositions and methods | Jul 19, 2011 |
| US 8,093,296 | Concomitant administration, clinical methods | Jan 10, 2012 |
| US 8,093,297 | Concomitant administration (ketoconazole, ritonavir) | Jan 10, 2012 |
| US 8,093,298 | Colchicine and macrolides | Jan 10, 2012 |
| US 8,097,655 | Drug interaction alerts and dispensing warnings | Jan 17, 2012 |
| US 8,415,395 | Ultrapure colchicine compositions | Apr 9, 2013 |
| US 8,415,396 | Colchicine compositions and methods | Apr 9, 2013 |
| US 8,440,721 | Concomitant administration, dosing guidance | May 14, 2013 |
| US 8,440,722 | Drug-drug interaction alert systems | May 14, 2013 |